Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer

We hypothesized that aberrations activating epidermal growth factor receptor (EGFR) via dimerization would be more sensitive to anti-dimerization agents (e.g., cetuximab). EGFR exon 19 abnormalities (L747_A750del; deletes amino acids LREA) respond to reversible EGFR kinase inhibitors (TKIs). Exon 20...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsigelny, Igor F., Wheler, Jennifer J., Greenberg, Jerry P., Kouznetsova, Valentina L., Stewart, David J., Bazhenova, Lyudmila, Kurzrock, Razelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467419/
https://www.ncbi.nlm.nih.gov/pubmed/25760241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467419/
https://www.ncbi.nlm.nih.gov/pubmed/25760241

Ejemplares similares